Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects

References

• Torabi A, Cleland JG, Khan NK, et al. The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J. 2008;29:859–870. doi:10.1093/eurheartj/ehn096
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Pedersen OD; on behalf of the TRACE study group. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol. 1996;78:1124–1128. doi:10.1016/S0002-9149(96)00576-0
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence NG185 – acute Coronary Syndromes. London: NICE; 2020. Available from: nice.org.uk/guidance/ng185. Accessed July 1, 2021.
   Google Scholar
• Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737. doi:10.1136/bmj.318.7200.1730
   PubMed Web of Science ®Google Scholar
• Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail. 2000;2:333–340. doi:10.1016/S1388-9842(00)00100-8
   PubMed Web of Science ®Google Scholar
• The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction inpatients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390. doi:10.1016/S0140-6736(00)04560-8
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L. Long term ACE‐inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581. doi:10.1016/S0140-6736(00)02212-1
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–2200. doi:10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37–46.
   PubMed Web of Science ®Google Scholar
• Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21:415. doi:10.1186/s13063-020-4214-6
   PubMed Web of Science ®Google Scholar
• Køber L, Torp pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676. doi:10.1056/NEJM199512213332503
   PubMed Web of Science ®Google Scholar
• Study TA. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–828.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677. doi:10.1056/NEJM199209033271001
   PubMed Web of Science ®Google Scholar
• Wu J, Hall AS; Gale CP on behalf of the AIREX Study Investigators. Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure. Heart. 2021;107:389–395. doi:10.1136/heartjnl-2020-316823
   PubMed Web of Science ®Google Scholar
• Vecchio C. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343:1115–1122.
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, Flather M. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669–685.
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J. Effects of losartan captopril on mortality morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–760. doi:10.1016/S0140-6736(02)09895-1
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906. doi:10.1056/NEJMoa032292
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. doi:10.1056/NEJMoa030207
   PubMed Web of Science ®Google Scholar
• Miller RJ, Howlett JG. Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction. BMC Cardiovasc Disord. 2015;15:46. doi:10.1186/s12872-015-0033-1
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885. doi:10.1016/S0140-6736(10)61198-1
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang X, Chen J, et al. Effectiveness and safety of ivabradine in the treatment of acute myocardial infarction: a systematic review and meta-analysis. Ann Palliat Med. 2021;10:4523–4531. doi:10.21037/apm-21-563
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, Carson P; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057. doi:10.1056/NEJMoa042934
   PubMed Web of Science ®Google Scholar
• Farag M, Mabote T, Shoaib A, et al. Hydralazine and nitrates alone or combined for the management of chronic heart failure: a systematic review. Int J Cardiol. 2015;196:61–69. doi:10.1016/j.ijcard.2015.05.160
   PubMed Web of Science ®Google Scholar
• Wiggers H, Køber L, Gislason G, et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): a 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137–146.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. doi:10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Bulluck H, Chan MHH, Paradies V, et al. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis. J Cardiovasc Magn Reson. 2018;20:72. doi:10.1186/s12968-018-0494-3
   PubMed Web of Science ®Google Scholar
• Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet. 1980;2:989–994.
   PubMed Web of Science ®Google Scholar
• Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147–152. doi:10.1056/NEJM199007193230302
   PubMed Web of Science ®Google Scholar
• Jonker JJ, Vanbergen PF. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet. 1994;343:499–503.
   PubMed Web of Science ®Google Scholar
• Moulson N, LaHaye SA, Bertrand OF, MacHaalany J. Prophylactic warfarin post anterior ST-elevation myocardial infarction: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2017;18:559–564. doi:10.1016/j.carrev.2017.05.002
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. doi:10.1056/NEJMoa1112277
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330. doi:10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom JW, Bosch J, et al.; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:205–218.
   PubMed Web of Science ®Google Scholar
• Zannad F, Anker SD, Byra WM, et al.; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379:1332–1342. doi:10.1056/NEJMoa1808848
   PubMed Web of Science ®Google Scholar
• Nygaard MH, Hvas AM, Grove EL. Efficacy and safety of oral anticoagulants in patients with systolic heart failure in sinus rhythm: a systematic review and meta-analysis of randomized controlled trials and cohort studies. TH Open. 2020;4:e383–e392. doi:10.1055/s-0040-1720961
   PubMedGoogle Scholar
• Alexander JH, Becker RC, Bhatt DL, et al.; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708. doi:10.1056/NEJMoa1105819
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Rivaroxaban for Preventing Adverse Outcomes After Acute Management of Acute Coronary Syndrome. Technology appraisal guidance [TA335]; 2015.
   Google Scholar
• Hayıroğlu Mİ, Keskin M, Uzun AO, et al. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock. Heart Lung Circ. 2019;28:237–244. doi:10.1016/j.hlc.2017.10.023
   PubMed Web of Science ®Google Scholar
• de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27:569–581. doi:10.1093/eurheartj/ehi696
   PubMed Web of Science ®Google Scholar
• Zachariah D, Brown R, Kanagala P, et al. The impact of age and chronic kidney disease on secondary prevention post-primary percutaneous coronary intervention. QJM. 2014;107:185–192. doi:10.1093/qjmed/hct222
   PubMed Web of Science ®Google Scholar
• Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904–910.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi:10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Pellicori P, Urbinati A, Shah P, et al. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur J Heart Fail. 2017;19:768–778. doi:10.1002/ejhf.788
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al.; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609–1620. doi:10.1056/NEJMoa1908655
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121–128. doi:10.1016/S0140-6736(20)30748-0
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Diaz R, Felker GM, et al.; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384:105–116. doi:10.1056/NEJMoa2025797
   PubMed Web of Science ®Google Scholar
• Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23:1040–1048. doi:10.1002/ejhf.2191
   PubMed Web of Science ®Google Scholar
• Presented by Dr. Marc Pfeffer at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021), May 15, 2021.
   Google Scholar
• National Institute for Health and Clinical Excellence QS103. Chronic heart failure in adults. London: NICE; 2018. Available from: nice.org.uk/guidance/qs9/chapter/List-of-quality-statements. Accessed October 26, 2021.
   Google Scholar
• Clinicaltrials.gov. EMPACT-MI: a Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction. Available from: https://clinicaltrials.gov/ct2/show/NCT04509674. Accessed July 1, 2021.
   Google Scholar
• Clinicaltrials.gov. Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack (DAPA-MI). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04564742. Accessed July 1, 2021.
   Google Scholar
• Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505. doi:10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838–1847. doi:10.1056/NEJMoa2021372
   PubMed Web of Science ®Google Scholar